Another example is Alnylam and Novartis' Leqvio (inclisiran), a PCSK9-targeting RNAi drug approved as a twice-yearly therapy for high cholesterol that has also been earmarked for early access in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback